Zydus Cadila To Make Gilead's Potential COVID-19 Drug Remdesivir
Remdesivir, intravenously administered in hospitals, has already been approved for emergency use in severely-ill patients in the United States, India and South Korea.13-06-2020
13-06-2020
CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus signs a non exclusive licensing agreement with Gilead Sciences Inc., to manufacture and market Remdesivir12-06-2020
CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper publication12-06-2020
CADILA HEALTHCARE LTD. - 532321 - Large Corporate
Disclosure with regard to Large Corporate05-06-2020
CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus Cadila receives final approval from USFDA for Atazanavir Capsulres05-06-2020
Cadila Healthcare share price rises 3% on EIR from USFDA
The USFDA had conducted an inspection at the facility from 2 to 9 March, 2020.29-05-2020
Three employees of Cadila Pharmaceuticals die of coronavirus in Gujarat
Ahmedabad district, which is worst-hit by the coronavirus pandemic, so far recorded 9,724 cases and 645 deaths23-05-2020
Zydus Cadila supplies 30,000 COVID KAVACH Elisa test kits to ICMR
The kits, to be used for antibody detection of Covid-19, have been manufactured in collaboration (via technology transfer) with ICMR-NIV of Pune for surveillance purposes21-05-2020
CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus supplies first batch of 30,000 COVID KAVACH ELISA tests to ICMR, free of cost21-05-2020